ponesimod (Ponvory)

Indications

• treatment of relapsing forms of multiple sclerosis, including
  • clinically isolated syndrome
  • relapsing-remitting disease
  • active secondary progressive disease

Contraindications

• pregnancy
• need for vaccination

Dosage

• 20 mg PO QD

Pharmacokinetics

• pharmacologic effects wear off in 1-2 weeks for most patients*

* shortest 12 life among sphingosine-1 phosphate receptor modulators

Monitor

• continuous electrocardiographic monitoring for 24 hours after 1st dose (probably not necessary)
• ophthalmoscopy
• serum transaminases
• complete blood count (CBC)

Adverse effects

• serious infections
• breathing problems
• liver problems
• hypertension
• skin cancer
• macular edema may occur
• bradycardia when 1st darting drug

Mechanism of action

• selective modulator of sphingosine-1 phosphate receptor
• reduces circulating lymphocytes trapping them in lymph nodes, precluding the lymphocytes from entering the central nervous system & damaging myelin

More general terms

• neurologic agent

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=11363176
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=11224984